Comprehensive medication guide to Mavyret including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$5/month with commercial insurance and the AbbVie savings copay card; $0 with Medicaid; $0–$2,100 out-of-pocket for Medicare Part D (capped at $2,100 in 2026); ~$12/month with Medicare Low Income Subsidy (Extra Help). Prior authorization required on most plans.
Estimated Cash Pricing
$14,000–$17,000 retail for an 8-week supply (84 tablets) without insurance; with the SingleCare discount card, approximately $12,900. No generic version of Mavyret is currently available.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Mavyret is a prescription antiviral medication manufactured by AbbVie. Its active ingredients are glecaprevir (100 mg) and pibrentasvir (40 mg), a fixed-dose combination of two direct-acting antivirals (DAAs). It is the first and only pangenotypic direct-acting antiviral approved by the FDA to treat both acute and chronic hepatitis C virus (HCV) infection in adults and children 3 years and older.
First approved in August 2017 for chronic HCV, Mavyret received a major label expansion in June 2025 to include acute HCV infection—making it the only DAA approved for this indication. With cure rates of 96–98% in treatment-naive patients and a short 8-week treatment course for most, Mavyret represents one of the most effective oral treatments in modern medicine.
Mavyret is taken as 3 tablets once daily with food. It is available in tablets (100 mg/40 mg per tablet) and oral pellets (50 mg/20 mg per packet) for patients who cannot swallow tablets. The standard adult dose is 300 mg glecaprevir and 120 mg pibrentasvir per day.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Mavyret contains two antivirals that each target a different protein the hepatitis C virus needs to survive and replicate. Glecaprevir is an HCV NS3/4A protease inhibitor—it blocks the viral enzyme that cuts a long precursor protein into the functional components the virus needs. Without this cleavage, the virus cannot assemble working copies of itself.
Pibrentasvir is a second-generation HCV NS5A inhibitor. NS5A is essential for both viral RNA replication and the assembly of new viral particles. By blocking NS5A, pibrentasvir disrupts both copying and packaging of the virus simultaneously.
By attacking the hepatitis C virus at two different points in its life cycle simultaneously, Mavyret dramatically reduces the chance that any variant of the virus can develop resistance. This dual-target strategy is why Mavyret achieves 96–98% cure rates across all six HCV genotypes in 8 weeks.
300 mg/120 mg (3 tablets) — tablet
Standard adult daily dose: 3 tablets (100 mg/40 mg each) taken together once daily with food
100 mg/40 mg — tablet
Individual tablet strength: glecaprevir 100 mg / pibrentasvir 40 mg
50 mg/20 mg per packet — oral pellets
Pediatric/alternative formulation: oral pellets for patients who cannot swallow tablets; sprinkled on soft food
Mavyret is not on the FDA's official drug shortage list as of 2026. AbbVie continues to manufacture and supply it without disruption. However, patients commonly struggle to fill their Mavyret prescription for systemic reasons: prior authorization requirements from insurance (which can take 3–14 days), mandatory specialty pharmacy routing by many insurance plans, and the simple fact that most retail pharmacies don't keep Mavyret in stock due to its $14,000+ price tag and infrequent prescription volume.
The best way to find a pharmacy near you that has Mavyret in stock is to use medfinder. medfinder calls pharmacies near you to check stock and fill capability for Mavyret, and texts you the results. Specialty pharmacies such as Accredo, CVS Specialty, Walgreens Specialty, and Optum Rx are the most reliable sources for Mavyret dispensing.
Mavyret is not a controlled substance and requires no special DEA certification to prescribe. Any licensed healthcare provider with full prescribing authority in their state can prescribe it. Because HCV treatment requires specific lab testing and prior authorization management, providers with hepatitis C experience are preferred, but it is not limited to specialists.
Hepatologists — liver specialists; most experienced with HCV treatment and specialty pharmacy logistics
Gastroenterologists — routinely manage HCV; often the most accessible specialist
Infectious disease specialists — especially for HIV/HCV co-infected patients
Primary care physicians (PCPs) — increasingly prescribing Mavyret, especially in underserved areas
Nurse practitioners (NPs) and physician assistants (PAs) — can prescribe in most states, particularly in GI and ID practices
Telehealth providers licensed in the patient's state can also prescribe Mavyret, provided they have access to the necessary laboratory results. Several telehealth platforms specialize in HCV treatment and manage prior authorization and specialty pharmacy routing as part of their service, making remote treatment more accessible than ever in 2026.
No. Mavyret (glecaprevir/pibrentasvir) is not a controlled substance and has no DEA scheduling. It does not have abuse potential and is not associated with dependence. Any licensed prescriber in the United States with a valid prescription pad can prescribe Mavyret—no special DEA waiver, DATA 2000 waiver, or certification is required.
Mavyret can be dispensed by any licensed pharmacy or specialty pharmacy that stocks it, and it can be sent via mail order. The primary prescribing considerations are not related to scheduling but to clinical appropriateness: verifying HCV genotype, ruling out contraindications (especially Child-Pugh B/C liver disease and concurrent atazanavir or rifampin use), and testing for HBV co-infection before initiation.
Mavyret is generally well-tolerated. The most common side effects reported in clinical trials are:
Headache
Fatigue and asthenia (weakness)
Nausea
Diarrhea
Itching (pruritus)
Mavyret carries a BOXED WARNING for the following serious risk:
Hepatitis B reactivation: Can cause fulminant hepatitis, hepatic failure, and death in HCV/HBV co-infected patients. All patients must be tested for HBV before starting Mavyret.
Hepatic decompensation/failure: Post-marketing cases have been reported, primarily in patients with pre-existing liver impairment.
Hypoglycemia in diabetic patients: As HCV is cleared and liver function improves, blood glucose control can change significantly. Monitor closely.
Know what you need? Skip the search.
Epclusa (sofosbuvir/velpatasvir)
Pangenotypic, once daily for 12 weeks; generic available; approved for decompensated cirrhosis with ribavirin; interacts with PPIs and antacids
Harvoni (ledipasvir/sofosbuvir)
Genotypes 1, 4, 5, 6 only; 8–12 weeks; generic available; interacts with PPIs and antacids
Zepatier (elbasvir/grazoprevir)
Genotypes 1 and 4 only; 12–16 weeks; good option for chronic kidney disease patients
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)
All genotypes; 12 weeks; indicated for patients who failed prior DAA therapy, especially NS5A-experienced
Prefer Mavyret? We can find it.
Atazanavir (Reyataz)
majorDramatically increases glecaprevir levels (6.5-fold AUC increase); severe ALT/AST elevations risk
Rifampin (Rifadin)
majorPotent CYP3A4/P-gp inducer; dramatically reduces Mavyret levels, causing treatment failure
Atorvastatin
majorMavyret increases atorvastatin 8-fold via OATP1B1/3 inhibition; severe myopathy/rhabdomyolysis risk
Carbamazepine (Tegretol)
majorStrong CYP3A4 inducer; significantly reduces Mavyret levels; can cause treatment failure
St. John's Wort
majorHerbal P-gp/CYP3A4 inducer; significantly reduces Mavyret blood levels
Darunavir (Prezista)
moderateP-gp/CYP3A4 inhibitor; increases Mavyret levels; avoid combination
Cyclosporine (>100 mg/day)
moderateSignificantly increases Mavyret levels at higher cyclosporine doses; caution required
Simvastatin/Lovastatin
moderateIncreased statin exposure due to OATP1B1/3 inhibition; myopathy risk
Warfarin (Coumadin)
moderateLiver function changes during HCV clearance can alter warfarin metabolism; monitor INR closely
Digoxin
moderateP-gp inhibition by Mavyret increases digoxin levels; monitor serum digoxin
Mavyret represents a remarkable advance in the treatment of hepatitis C. In a single 8-week course of 3 daily tablets, it cures 96–98% of patients regardless of HCV genotype. For a disease that once required a year of difficult interferon-based therapy with limited success, this transformation is extraordinary. If you have hepatitis C—acute or chronic—and are a candidate for Mavyret, the medical case for treatment is compelling.
The main practical challenges are insurance-related: prior authorization, specialty pharmacy routing, and cost. With the right assistance programs, most patients can access Mavyret at little or no cost. The AbbVie savings card reduces copays to $5/month for commercially insured patients. myAbbVie Assist provides it free to eligible uninsured patients. HealthWell Foundation and other programs help Medicare patients.
If you've secured insurance coverage or financial assistance and still need help locating Mavyret at a pharmacy near you, medfinder contacts pharmacies on your behalf to find which ones have Mavyret in stock and can fill your prescription. Don't let a prescription search delay your path to being cured.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini